Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

61-80 of 991 trials

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Cost ReimbursementEndocrinologyOrthopedics and Traumatology

Semaglutide for Glucose Intolerance in Women with Prior Gestational Diabetes

We are studying whether semaglutide can help women with a history of gestational diabetes manage glucose intolerance and reduce the risk of developing type 2 diabetes.

Prediabetes>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyGynecology and Obstetrics

Primary IgA Nephropathy: RO7434656 Treatment Study

We are testing a new medication to see if it helps reduce protein in urine and improves kidney function in patients with Primary IgA Nephropathy at high risk of progression. The study will also evaluate safety and fatigue levels.

IgA Nephropathy>2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNephrology

Systemic Lupus Erythematosus: ESK-001 Treatment Study

We are investigating a new medication, ESK-001, for adults with systemic lupus erythematosus to see if it helps improve disease activity and is safe to use. Participants will receive either ESK-001 or a placebo in this study.

Systemic Lupus Erythematosus1-2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Calcific Aortic Valve Stenosis: Pelacarsen (TQJ230) Study

We are studying whether the medication pelacarsen can slow the progression of calcific aortic valve stenosis in patients with high lipoprotein(a) levels. This trial will help us understand its effects compared to a placebo.

Calcific Aortic Valve Stenosis>2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Cost ReimbursementCardiologyInternal Medicine

Semaglutide for Reducing GI Issues in Chemotherapy Patients

We are studying whether semaglutide can help lessen gastrointestinal problems in patients undergoing high-dose chemotherapy and stem cell transplantation. The trial also looks at its safety and effects on gut health.

Mucositis and Systemic Inflammation3-6 monthsEfficacy phase (II)Standard Medicines Cost ReimbursementGastroenterologyOncology

Atrial Fibrillation: WOEST-3 Study

We are exploring a new antithrombotic strategy for patients with atrial fibrillation undergoing heart procedures. The goal is to see if this approach reduces bleeding and heart-related risks compared to standard treatment.

Atrial FibrillationAcute Coronary SyndromeChronic Coronary Syndrome1-2 yearsMonitoring phase (IV)No Placebo Standard Medicines Cost ReimbursementCardiologyInternal Medicine

Kidney Disease: Iptacopan (LNP023) Study

We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.

Idiopathic Immune Complex Mediated Membranoproliferative GlomerulonephritisConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineNephrology

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementAllergologyHematologyInternal Medicine

Hypogammaglobulinemia: XEMBIFY Treatment Study

We are testing whether XEMBIFY, combined with standard treatment, can help prevent infections in patients with hypogammaglobulinemia linked to blood cancers. This study compares its effects to a placebo treatment.

Chronic Lymphocytic Leukaemia1-2 yearsConfirmation phase (III)>20 visits Investigational Medicines Cost ReimbursementHematologyInfectious DiseasesOncology

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost ReimbursementOrthopedics and TraumatologyPediatrics

Bladder Cancer Treatment: Chemoablation vs. Standard Care

We are studying whether a new chemoablation method is more effective than standard bladder surgery and chemotherapy for patients with recurrent non-muscle invasive bladder cancer. This may help reduce recurrence rates and improve long-term outcomes.

Recurrent Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Cost ReimbursementOncologyUrology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyPediatrics

AR Positive Triple-Negative Breast Cancer: Bicalutamide and Abemaciclib Study

We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.

Locally Advanced Unresectable or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyInternal Medicine

Focal-Onset Seizures: Study of XEN1101

We are testing a new medication, XEN1101, to see if it can help reduce the frequency of focal-onset seizures. This study compares its effects to a placebo in participants with this condition.

Focal Epilepsy6-12 monthsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurology

XEN1101 for Primary Generalized Tonic-Clonic Seizures

We are studying whether XEN1101 can help reduce the frequency of seizures in people with Primary Generalized Tonic-Clonic Seizures compared to a placebo. This trial aims to understand its safety and impact on seizure control.

Generalized Tonic-Clonic SeizureConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Search Clinical Trials in the European Union